{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:39:24Z","timestamp":1767847164142,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T00:00:00Z","timestamp":1372118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10549-013-2597-8","type":"journal-article","created":{"date-parts":[[2013,6,24]],"date-time":"2013-06-24T06:28:13Z","timestamp":1372055293000},"page":"73-82","source":"Crossref","is-referenced-by-count":31,"title":["A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer"],"prefix":"10.1007","volume":"140","author":[{"given":"R. Charles","family":"Coombes","sequence":"first","affiliation":[]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Souli\u00e9","sequence":"additional","affiliation":[]},{"given":"Concepcion","family":"Peraire","sequence":"additional","affiliation":[]},{"given":"Veronique","family":"Fohanno","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Kornowski","sequence":"additional","affiliation":[]},{"given":"Tauhid","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"issue":"1\u20133","key":"2597_CR1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0039-128X(83)90077-6","volume":"50","author":"VH James","year":"1987","unstructured":"James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ (1987) Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50(1\u20133):269\u2013279","journal-title":"Steroids"},{"issue":"1","key":"2597_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/jcem-59-1-29","volume":"59","author":"SJ Santner","year":"1984","unstructured":"Santner SJ, Feil PD, Santen RJ (1984) In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59(1):29\u201333","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2597_CR3","first-page":"2762","volume":"63","author":"T Suzuki","year":"2003","unstructured":"Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63(11):2762\u20132770","journal-title":"Cancer Res"},{"issue":"2","key":"2597_CR4","first-page":"377","volume":"59","author":"T Utsumi","year":"1999","unstructured":"Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K, Harada N (1999) Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 59(2):377\u2013381","journal-title":"Cancer Res"},{"issue":"6","key":"2597_CR5","first-page":"2288","volume":"9","author":"Y Miyoshi","year":"2003","unstructured":"Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y, Noguchi S (2003) High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 9(6):2288\u20132293","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2597_CR6","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr746","volume":"6","author":"N Yoshimura","year":"2004","unstructured":"Yoshimura N, Harada N, Bukholm I, Karesen R, Borresen-Dale AL, Kristensen VN (2004) Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Res 6(2):R46\u2013R55. doi: 10.1186\/bcr746","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2597_CR7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-05-1996","volume":"12","author":"SJ Stanway","year":"2006","unstructured":"Stanway SJ, Purohit A, Woo LW, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BV, Reed MJ, Coombes RC (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 12(5):1585\u20131592. doi: 10.1158\/1078-0432.CCR-05-1996","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2597_CR8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-010-0785-3","volume":"120","author":"N Chanplakorn","year":"2010","unstructured":"Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H (2010) Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 120(3):639\u2013648. doi: 10.1007\/s10549-010-0785-3","journal-title":"Breast Cancer Res Treat"},{"key":"2597_CR9","unstructured":"National Institute of Health National Cancer Institute. Common criteria for adverse events v3.0 (CTCAE) (2006). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed 4 April 2013"},{"issue":"10","key":"2597_CR10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664\u20131670. doi: 10.1200\/JCO.2007.13.5822","journal-title":"J Clin Oncol"},{"issue":"5","key":"2597_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001813-199806000-00008","volume":"9","author":"PF Bruning","year":"1998","unstructured":"Bruning PF, Bonfrer JM, Paridaens R, Nooij M, Klijn JG, Beex LV, Bruynseels J, Piccart MJ (1998) Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group). Anticancer Drugs 9(5):419\u2013425","journal-title":"Anticancer Drugs"},{"issue":"6","key":"2597_CR12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7","volume":"83","author":"AU Buzdar","year":"1998","unstructured":"Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials Arimidex Study Group. Cancer 83(6):1142\u20131152. doi: 10.1002\/(SICI)1097-0142(19980915)83:6<1142:AID-CNCR13>3.0.CO;2-5","journal-title":"Cancer"},{"issue":"7","key":"2597_CR13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1124\/dmd.111.038315","volume":"39","author":"V Ventura","year":"2011","unstructured":"Ventura V, Sola J, Celma C, Peraire C, Obach R (2011) In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification. Drug Metab Dispos 39(7):1235\u20131246. doi: 10.1124\/dmd.111.038315","journal-title":"Drug Metab Dispos"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2597-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2597-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:47:18Z","timestamp":1559234838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2597-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,25]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2597-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,25]]}}}